Recombinant Adenovirus (Ad) vectors provide a highly versatile system of mammalian gene transfer and are widely used in basic research, in vaccine development, and for a variety of gene therapy applications, particularly for cancer gene therapy. These applications are facilitated by several important advantages of Ad over other vectors, including convenient and simple methods of vector construction, the efficient infection of quiescent cells, and their capacity to incorporate large segments of heterologous DNA. The number of gene therapy trials employing Ad vectors is expanding very rapidly. In parallel, developing Ad vectors for gene therapy has tremendously advanced our knowledge in Ad biology on viral tropism, duration of gene expression, toxicity, and immunogenicity. These advances have suggested a differential application of the different types of replication‐deficient and replication‐competent Ad vectors in gene medicine.